Virion Therapeutics Reports Positive First-in-human, First-in-class, Phase 1b Immunogenicity Data of VRON-0200, a Novel Checkpoint Modifier for HBV Functional Cure at EASL Congress

Virion Therapeutics, LLC announced positive immunologic and continued safety and tolerability data, from the first-ever human study of its novel, first-in-class, checkpoint modifier immunotherapy, VRON-0200, for HBV functional cure, presented by Professor Ed Gane, M.D., from the University of Auckland, as a late breaker at the EASL Congress 2024 in Milan, Italy.